Skip to content

Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19

Effectiveness and Safety of Respiratory Training Devices in the Prevention and Severity of COVID-19: A Randomized Controlled Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04326114
Enrollment
240
Registered
2020-03-30
Start date
2020-07-26
Completion date
2020-12-20
Last updated
2020-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disease, Infectious, Effectiveness, Respiratory Disease, Safety Issues

Brief summary

A randomized controlled clinical trial will be carried out using inspiratory and expiratory training devices on healthy subjects recruited in social networks and university environments. The aim will be to determine the effectiveness and safety in the prevention and severity of COVID-19 disease by a respiratory training with inspiratory and expiratory devices.

Interventions

DEVICEInspiratory training device

Inspiratory training by a Power-breath device

DEVICEExpiratory training device

Expiratory training a Winner-flow device

Sponsors

Universidad Complutense de Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Healthy subjects

Exclusion criteria

* Drugs * Surgery * Neurology diseases * Rheumatic diseases * Systemic diseases * Smokers

Design outcomes

Primary

MeasureTime frameDescription
COVID-19 disease diagnosisChange from Baseline COVID-19 disease diagnosis at 8 weeksDichotomous categorical variable measured by yes or no responses

Secondary

MeasureTime frameDescription
COVID-19 disease symptoms severityChange from Baseline COVID-19 disease symptoms severity at 8 weeksDichotomous categorical variable measured by slight or severe responses
Adverse effectsChange from Baseline adverse effects at 8 weeksPolytomous categorical variable measured by adverse effects responses

Contacts

Primary ContactCésar Calvo Lobo, PhD
cescalvo@ucm.es91 394 1544

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026